Zimmer Biomet (NYSE:ZBH) Stock Rating Lowered by Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

ZBH has been the topic of several other research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. Canaccord Genuity Group decreased their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. BTIG Research reissued a “buy” rating and set a $112.00 target price on shares of Zimmer Biomet in a research report on Tuesday. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Up 1.2%

ZBH opened at $96.32 on Friday. The company has a market capitalization of $19.09 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 1.95 and a beta of 0.62. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.39. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The business has a 50-day moving average of $90.10 and a 200-day moving average of $95.64.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors have recently made changes to their positions in ZBH. Rakuten Investment Management Inc. bought a new stake in Zimmer Biomet in the third quarter valued at approximately $37,307,000. Sector Gamma AS grew its holdings in shares of Zimmer Biomet by 28.0% in the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after buying an additional 24,847 shares during the period. Resona Asset Management Co. Ltd. increased its position in shares of Zimmer Biomet by 5.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock valued at $6,197,000 after buying an additional 3,634 shares in the last quarter. SG Americas Securities LLC raised its stake in Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after buying an additional 13,812 shares during the period. Finally, Border to Coast Pensions Partnership Ltd lifted its holdings in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after acquiring an additional 22,104 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.